Skip to Content
Merck

Skip To

1202005

USP

Dihydroergotamine mesylate

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Dihydroergotamine methanesulfonate salt

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice
500 mg
Check Cart for Availability
€ 407,00

About This Item

Empirical Formula (Hill Notation):
C33H37N5O5 · CH4O3S
CAS Number:
Molecular Weight:
679.78
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:

€ 407,00


Check Cart for Availability

Request a Bulk Order
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


grade

pharmaceutical primary standard

agency

USP

API family

dihydroergotamine

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1C[C@H](CN2C)C(=O)N[C@]5(C)O[C@]6(O)N([C@@H](Cc7ccccc7)C(=O)N8CCC[C@@]68[H])C5=O)c34

InChI

1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1

InChI key

ADYPXRFPBQGGAH-WVVAGBSPSA-N

Application

Dihydroergotamine mesylate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Biochem/physiol Actions

Agonist at vascular serotonin receptors; partial agonist at α-adrenergic and dopamine D2 receptors; vasoconstrictor.
Vascular serotonin receptor agonist; vasoconstrictor.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
Y0000831D19500001440003
grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

grade

pharmaceutical primary standard

manufacturer/tradename

USP

manufacturer/tradename

EDQM

manufacturer/tradename

EDQM

manufacturer/tradename

USP

format

neat

format

neat

format

neat

format

neat

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

application(s)

pharmaceutical (small molecule)

storage temp.

2-8°C

storage temp.

-

storage temp.

2-8°C

storage temp.

2-8°C

API family

dihydroergotamine

API family

dihydroergotamine

API family

dihydroergotamine

API family

methysergide


Still not finding the right product?

Explore all of our products under Dihydroergotamine mesylate


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



S B Shrewsbury et al.
British journal of pharmacology, 154(6), 1254-1265 (2008-05-27)
The effects of intrapulmonary artery (i.p.a.) administration of dihydroergotamine mesylate (DHE) were evaluated. Conscious beagle dogs (n=4) were given DHE via the i.p.a. or i.v. route as two 0.014 mg kg(-1) doses and a 0.14 mg kg(-1) dose given 60
Xiaoyan Chen et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 768(2), 267-275 (2002-03-13)
A sensitive and specific procedure for the simultaneous determination of dihydroergotamine (DHE) and its 8'-hydroxylated metabolite (8'-OH-DHE) in human plasma was developed and validated. The analytes were extracted from plasma samples by liquid-liquid extraction, separated through a Zorbax C18 column
Drugs in R&D, 4(6), 376-377 (2003-10-31)
MT 300 is an injectable formulation of dihydroergotamine mesylate (DHE; a serotonin 5-HT1 receptor agonist) that is being developed by POZEN for the acute treatment of migraine. POZEN intends to present MT 300 as a prefilled syringe that can be



Global Trade Item Number

SKUGTIN
1202005-250MG04061838712905

Questions

Reviews

No rating value

Active Filters